TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY).

Cameron R Wolfe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.